News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
131 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17535)
Month
January (2946)
February (2976)
March (2714)
April (2913)
May (3639)
June (2347)
Day
2 (2)
3 (145)
4 (188)
5 (190)
6 (124)
7 (71)
10 (179)
11 (91)
12 (168)
13 (122)
14 (57)
17 (142)
18 (120)
19 (151)
20 (179)
21 (55)
24 (93)
25 (131)
26 (123)
27 (118)
28 (134)
31 (131)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
Day
2
3
4
5
6
7
10
11
12
13
14
17
18
19
20
21
24
25
26
27
28
31
Cardiovascular disease
Lilly’s RNA Silencer Lowers Key Cardiovascular Biomarker by Almost 94%
BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in development to date” in the competitive Lp(a) space, where drugs are designed to lower the risk of cardiovascular events such as heart attack and stroke.
March 31, 2025
·
2 min read
·
Tristan Manalac
FDA
Marks’ Sudden Departure From FDA Magnifies Uncertainty, Sends Biopharma Shares Down
The stock market—and biotech insiders—reacted negatively to the allegedly forced resignation of CBER Director Peter Marks, who said RFK Jr. does not seek “truth and transparency” but rather “subservient confirmation of his misinformation and lies.”
March 31, 2025
·
3 min read
·
Heather McKenzie
Press Releases
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
March 31, 2025
·
8 min read
Press Releases
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
March 31, 2025
·
11 min read
Press Releases
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
March 31, 2025
·
5 min read
Press Releases
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
March 31, 2025
·
8 min read
Press Releases
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
March 31, 2025
·
19 min read
Press Releases
Tr1X Announces Succession Plan: Appoints David de Vries CEO, Effective June 1; Bill Lis to Serve as Executive Chairman
March 31, 2025
·
3 min read
Press Releases
Aptose Reports Year End 2024 Results and Corporate Highlights
March 31, 2025
·
12 min read
Press Releases
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
March 31, 2025
·
18 min read
Previous
2 of 14
Next
